NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
4.110
+0.900 (28.04%)
Aug 14, 2026, 4:00 PM EDT - Market closed
NeOnc Technologies Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed a quorum and approved all proposals, including director elections, an equity incentive plan amendment, and auditor ratification. No shareholder questions were received, and the meeting concluded with plans to file final voting results.
-
NEO100, delivered intranasally, showed a median overall survival of 26.09 months in recurrent IDH1 mutant high-grade glioma, far exceeding the historical six to nine months. The phase II-A trial met its primary endpoint with a PFS6 of 48.9%, and demonstrated durable disease control and favorable tolerability.